Now, it has decided to publish a special report on two of GSK's COPD therapies – Breo Ellipta (fluticasone ... to their respective fixed-dose generic alternatives or open generic combinations ...
Discontinue and treat if paradoxical bronchospasm occurs; use alternative therapy. Cardiovascular disease (esp. coronary insufficiency, arrhythmias, hypertension). Convulsive disorders.
Developed with US respiratory specialist firm Innoviva, the drug (known as Breo Ellipta in the US) is GSK’s follow up to its respiratory blockbuster Advair/Seretide, but won’t come close to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results